Research Institute of Molecular Pathology
The Research Institute of Molecular Pathology (IMP) is a biomedical research center, which conducts curiosity-driven basic research in the molecular life sciences.
Research Institute of Molecular Pathology
Laboratory at the IMP. Up to three research groups share a lab to support communication and exchange.
Research Institute of Molecular Pathology (IMP), outside view.
Split-level architecture blending different floors and functions of the new IMP building.
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.
Albert Boehringer founder of Boehringer Ingelheim in August 1885
Aerial footage of company's headquarters
Poster for Boeson baking powder, the first patented Boehringer Ingelheim product in year 1895